BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hui C, Leung N, Yuen S, Zhang H, Leung K, Lu L, Cheung SKF, Wong W, Lau GK; Hong Kong Liver Fibrosis Study Group. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007;46:395-401. [DOI: 10.1002/hep.21724] [Cited by in Crossref: 142] [Cited by in F6Publishing: 146] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical Gastroenterology and Hepatology 2015;13:2071-2087.e16. [DOI: 10.1016/j.cgh.2015.07.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 10.4] [Reference Citation Analysis]
2 Poynard T, Massard J, Rudler M, Varaud A, Lebray P, Moussalli J, Munteanu M, Ngo Y, Thabut D, Benhamou Y, Ratziu V. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: An overview of published trials. Gastroentérologie Clinique et Biologique 2009;33:916-22. [DOI: 10.1016/j.gcb.2009.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
3 Lau GK, Wang FS. Management of chronic hepatitis B e antigen-negative disease: another step forward. J Infect Dis 2012;205:7-9. [PMID: 22095767 DOI: 10.1093/infdis/jir694] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection - EASL Special Conference. J Hepatol. 2015;63:1238-1253. [PMID: 26150256 DOI: 10.1016/j.jhep.2015.06.026] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 10.4] [Reference Citation Analysis]
5 Tong MJ, Trieu J. Hepatitis B inactive carriers: clinical course and outcomes. J Dig Dis. 2013;14:311-317. [PMID: 23433008 DOI: 10.1111/1751-2980.12051] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
6 Wong GL, Chan HL, Yu Z, Chan H, Tse C, Wong VW. Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination: Fibrosis progression in hepatitis B. J Gastroenterol Hepatol 2013;28:1762-9. [DOI: 10.1111/jgh.12312] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
7 Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, Seo YS, Um SH, Lee JI, Lee KS, Lee CH, Tak WY, Kweon YO, Kang W, Paik YH, Lee JW, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther 2020;52:196-204. [PMID: 32452564 DOI: 10.1111/apt.15741] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
8 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
9 Lee HW, Chon YE, Kim BK, Yip TC, Tse YK, Wong GL, Wong VW, Chan HL, Ahn SH. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med 2021;84:68-73. [PMID: 33288393 DOI: 10.1016/j.ejim.2020.10.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
11 Chen F, Zhang J, Guo F, Wen B, Luo S, Yuan D, Lin Y, Ou W, Tang P, Dai G, Li F, Liu W, Qu X. Hepatitis B, C, and D virus infection showing distinct patterns between injection drug users and the general population: Epidemic patterns of hepatitis virus. Journal of Gastroenterology and Hepatology 2017;32:515-20. [DOI: 10.1111/jgh.13460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
12 Lai M, Liaw Y. Chronic Hepatitis B: Past, Present, and Future. Clinics in Liver Disease 2010;14:531-46. [DOI: 10.1016/j.cld.2010.05.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
13 Chu C, Liaw Y. Prognosis of immune-tolerant phase chronic hepatitis B. Gut 2018;67:988.1-988. [DOI: 10.1136/gutjnl-2017-315603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-1125/1/142] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH;  American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1064] [Article Influence: 165.6] [Reference Citation Analysis]
16 Attar BM. CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated. Clin Liver Dis (Hoboken). 2020;15:25-30. [PMID: 32104574 DOI: 10.1002/cld.893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Nousbaum JB. [A 23-year-old asymptomatic HBsAg positive woman]. Gastroenterol Clin Biol 2009;33:F56-9. [PMID: 19762187 DOI: 10.1016/j.gcb.2009.07.029] [Reference Citation Analysis]
18 Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, Lee HC, Lee YS. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:945-952. [PMID: 29055908 DOI: 10.1136/gutjnl-2017-314904] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 15.4] [Reference Citation Analysis]
19 Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009;51:403-10. [PMID: 19467727 DOI: 10.1016/j.jhep.2009.04.003] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 6.4] [Reference Citation Analysis]
20 Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R, Wu C. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat 2021;28:1025-33. [PMID: 33797145 DOI: 10.1111/jvh.13511] [Reference Citation Analysis]
21 Chung TH, Kim MC, Kim CS. Association between Hepatitis B Surface Antigen Seropositivity and Metabolic Syndrome. Korean J Fam Med. 2014;35:81-89. [PMID: 24724003 DOI: 10.4082/kjfm.2014.35.2.81] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
22 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053-2063. [PMID: 24954675 DOI: 10.1016/s0140-6736(14)60220-8] [Cited by in Crossref: 809] [Cited by in F6Publishing: 403] [Article Influence: 101.1] [Reference Citation Analysis]
24 Yu JH, Lee JI. Current role of transient elastography in the management of chronic hepatitis B patients. Ultrasonography. 2017;36:86-94. [PMID: 27956732 DOI: 10.14366/usg.16023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
25 Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology. 2009;49:S61-S71. [PMID: 19399798 DOI: 10.1002/hep.22930] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
26 Liaw YF. Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros. Dig Liver Dis 2010;42 Suppl 3:S293-7. [PMID: 20547317 DOI: 10.1016/S1590-8658(10)60519-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
27 Sun HH, Zhou DF, Zhou JY. The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation. J Med Virol. 2016;88:13-20. [PMID: 26104380 DOI: 10.1002/jmv.24306] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
28 Ghany MG. Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. Best Pract Res Clin Gastroenterol. 2017;31:299-309. [PMID: 28774412 DOI: 10.1016/j.bpg.2017.04.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
29 Lian JQ, Yang XF, Zhao RR, Zhao YY, Li Y, Zhang Y, Huang CX. Expression profiles of circulating cytokines, chemokines and immune cells in patients with hepatitis B virus infection. Hepat Mon 2014;14:e18892. [PMID: 24976843 DOI: 10.5812/hepatmon.18892] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
30 Gill US, Kennedy PT. Chronic hepatitis B virus in young adults: the need for new approaches to management. Expert Rev Anti Infect Ther 2014;12:1045-53. [PMID: 25052517 DOI: 10.1586/14787210.2014.940899] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci. 2011;56:3143-3162. [PMID: 21935699 DOI: 10.1007/s10620-011-1841-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
32 Chan HL, Wong GL, Tse CH, Chim AM, Yiu KK, Chan HY, Sung JJ, Wong VW. Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clin Gastroenterol Hepatol. 2009;7:1361-1366. [PMID: 19683072 DOI: 10.1016/j.cgh.2009.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 4.7] [Reference Citation Analysis]
33 Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29 Suppl 1:100-107. [PMID: 19207972 DOI: 10.1111/j.1478-3231.2008.01941.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 140] [Article Influence: 11.2] [Reference Citation Analysis]
34 He J, Zhou D, Tong G, Xing Y, Chen Y, Zhang X, Zhan B, Gao H, Zhou X, Xiong Y, Liu X, Peng L, Qiu M, Zheng Y. Efficacy and safety of a chinese herbal formula (invigorating kidney and strengthening spleen) in chronic hepatitis B virus carrier: results from a multicenter, randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med. 2013;2013:961926. [PMID: 23935692 DOI: 10.1155/2013/961926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Gill US, Kennedy PT. New insights in the management of chronic hepatitis B. Clin Med (Lond) 2015;15:191-6. [PMID: 25824074 DOI: 10.7861/clinmedicine.15-2-191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
36 Chien R, Liaw Y. Current treatment of chronic HBV infection: An Asian-Pacific perspective. Curr hepatitis rep 2009;8:154-60. [DOI: 10.1007/s11901-009-0022-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Chen EQ, Sun H, Feng P, Gong DY, Liu C, Bai L, Yang WB, Lei XZ, Chen LY, Huang FJ. Study of the expression levels of Hepatocyte nuclear factor 4 alpha and 3 beta in patients with different outcome of HBV infection. Virol J. 2012;9:23. [PMID: 22257755 DOI: 10.1186/1743-422x-9-23] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
38 Liao B, Wang Z, Lin S, Xu Y, Yi J, Xu M, Huang Z, Zhou Y, Zhang F, Hou J. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One 2013;8:e78672. [PMID: 24205292 DOI: 10.1371/journal.pone.0078672] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
39 Zhou K, Terrault N. Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy? AME Med J 2018;3:27. [PMID: 31058256 DOI: 10.21037/amj.2018.02.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Chen J, Xu CR, Xi M, Hu WW, Tang ZH, Zang GQ. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels. J Viral Hepat. 2017;24:573-579. [PMID: 28107601 DOI: 10.1111/jvh.12679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
41 Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014;20:401-13. [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Reference Citation Analysis]
42 Tong MJ, Hsu L, Hsien C, Kao JH, Durazo FA, Saab S, Blatt LM. A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol Int. 2010;4:516-522. [PMID: 20827410 DOI: 10.1007/s12072-010-9179-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
43 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.1] [Reference Citation Analysis]
44 Xing YF, Wei CS, Zhou TR, Huang DP, Zhong WC, Chen B, Jin H, Hu XY, Yang ZY, He Q, Jiang KP, Jiang JM, Hu ZB, Deng X, Yang F, Li FY, Zhao G, Wang LC, Mi YQ, Gong ZJ, Guo P, Wu JH, Shi WQ, Yang HZ, Zhou DQ, Tong GD. Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients. World J Gastroenterol 2020; 26(30): 4501-4522 [PMID: 32874061 DOI: 10.3748/wjg.v26.i30.4501] [Reference Citation Analysis]
45 Lok AS. Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? Hepatology 2010;51:1107-9. [DOI: 10.1002/hep.23496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
46 Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. Sci Rep 2019;9:2508. [PMID: 30792468 DOI: 10.1038/s41598-019-39043-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
47 Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol. 2008;2:553-562. [PMID: 19072403 DOI: 10.1586/17474124.2.4.553] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
48 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
49 Liaw Y. Natural History of Chronic Hepatitis B Virus Infection. In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 143-53. [DOI: 10.1002/9781118637272.ch10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Jafri SR, Lok AS. Antiviral Therapy for Chronic Hepatitis B. Clinics in Liver Disease 2010;14:425-38. [DOI: 10.1016/j.cld.2010.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
51 Yang HC, Shih YF, Liu CJ. Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. J Infect Dis 2017;216:S757-64. [PMID: 29156050 DOI: 10.1093/infdis/jix461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
52 Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51:435-444. [PMID: 19918971 DOI: 10.1002/hep.23348] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 9.9] [Reference Citation Analysis]
53 Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009;49:S129-37. [PMID: 19399799 DOI: 10.1002/hep.22931] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
54 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Zhao WF, Chen LY. Viral hepatitis B in children: clinical characteristics and antiviral treatment. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1624-1628 [DOI: 10.11569/wcjd.v19.i15.1624] [Reference Citation Analysis]
56 Seong G, Sinn DH, Kang W, Gwak GY, Choi MS, Lee JH, Koh KC, Woon Paik S, Paik YH. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. Eur J Gastroenterol Hepatol 2022;34:69-75. [PMID: 32925504 DOI: 10.1097/MEG.0000000000001915] [Reference Citation Analysis]
57 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-11] [Cited by in Crossref: 91] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
58 Chan HLY. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol 2019;34:501-6. [PMID: 30402981 DOI: 10.1111/jgh.14534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
59 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 21.8] [Reference Citation Analysis]
60 Marzio DHD, Hann HW. Then and now: The progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014; 20(2): 401-413 [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
61 Degertekin B, Lok AS. Update on viral hepatitis: 2007. Curr Opin Gastroenterol. 2008;24:306-311. [PMID: 18408458 DOI: 10.1097/mog.0b013e3282f70285] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
62 Sinn DH. [Natural History and Treatment Indications of Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:245-50. [PMID: 31765552 DOI: 10.4166/kjg.2019.74.5.245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Su T, Liao C, Liu C, Huang K, Tseng T, Yang H, Liu C, Chen P, Chen D, Kao J. Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. Radiology 2018;288:293-9. [DOI: 10.1148/radiol.2018171116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
64 Carneiro de Moura M, Marinho R. [Natural history and clinical manifestations of chronic hepatitis B virus]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:11-8. [PMID: 19100227 DOI: 10.1016/s0213-005x(08)76515-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Wu JZ, Huang RG, Yang XX. Differences in HBsAg and HBcAg expression in liver tissues between chronic hepatitis B patients with immunologic tolerance vs immune activity. Shijie Huaren Xiaohua Zazhi 2017; 25(7): 620-626 [DOI: 10.11569/wcjd.v25.i7.620] [Reference Citation Analysis]
66 Mai RY, Zeng J, Mo YS, Liang R, Lin Y, Wu SS, Piao XM, Gao X, Wu GB, Li LQ, Ye JZ. Artificial Neural Network Model for Liver Cirrhosis Diagnosis in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Ther Clin Risk Manag 2020;16:639-49. [PMID: 32764948 DOI: 10.2147/TCRM.S257218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Hui CK, Lau GK. Treatment of Hepatitis B e Antigen-negative Patients. Curr Treat Options Gastroenterol 2007;10:474-82. [PMID: 18221608 DOI: 10.1007/s11938-007-0047-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
68 Jin Y, Geng N, Zhao L, Li Y, Zheng L, Zhu W, Sheng Q, An Z, Wang J, Dou X, Bai H. The Prevalence of HBV Infection: A Retrospective Study of 13 Years in a Public Hospital of Northeast China. Viral Immunol 2020;33:99-104. [PMID: 31834847 DOI: 10.1089/vim.2019.0104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
69 Lo Re V, Wang L, Devine S, Baser O, Olufade T. Hepatic decompensation in patients with HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. Clin Infect Dis. 2014;59:1027-1031. [PMID: 24944235 DOI: 10.1093/cid/ciu476] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
70 Chien TL, Wang JH, Kee KM, Chen CH, Hung CH, Lu SN. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function. PLoS One 2016;11:e0166543. [PMID: 27935953 DOI: 10.1371/journal.pone.0166543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
71 Fonseca JC. Natural history of chronic hepatitis B. Rev Soc Bras Med Trop. 2007;40:672-677. [PMID: 18200423 DOI: 10.1590/S0037-86822007000600015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
72 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-S19. [PMID: 18304680 DOI: 10.1016/j.jhep.2008.01.011] [Cited by in Crossref: 107] [Cited by in F6Publishing: 106] [Article Influence: 7.6] [Reference Citation Analysis]
73 Chen C, Lee W, Yang H, Chang H, Jen C, Iloeje UH, Su J, Hsiao CK, Wang L, You S, Lu S, Chen C. Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma. Gastroenterology 2011;141:1240-1248.e2. [DOI: 10.1053/j.gastro.2011.06.036] [Cited by in Crossref: 152] [Cited by in F6Publishing: 142] [Article Influence: 13.8] [Reference Citation Analysis]
74 Huang R, Yang CC, Liu Y, Xia J, Su R, Xiong YL, Wang GY, Sun ZH, Yan XM, Lu S, Wu C. Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients. World J Gastroenterol 2015; 21(34): 9957-9965 [PMID: 26379400 DOI: 10.3748/wjg.v21.i34.9957] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
75 Wang YQ, Cao WJ, Gao YF, Ye J, Zou GZ. Serum interleukin-34 level can be an indicator of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol 2018; 24(12): 1312-1320 [PMID: 29599606 DOI: 10.3748/wjg.v24.i12.1312] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
76 Premkumar M, Chawla YK. Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia. Journal of Clinical and Experimental Hepatology 2022;12:144-54. [DOI: 10.1016/j.jceh.2021.08.023] [Reference Citation Analysis]
77 Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton). 2010;15:137-145. [PMID: 20470270 DOI: 10.1111/j.1440-1797.2009.01268.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 7.2] [Reference Citation Analysis]
78 Andreani T. HBV-carriers: When is monitoring and surveillance sufficient? (point of view). Clin Res Hepatol Gastroenterol 2011;35:813-8. [PMID: 21821479 DOI: 10.1016/j.clinre.2011.06.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
79 Choe HJ, Choe BH. What physicians should know about the management of chronic hepatitis B in children: East side story. World J Gastroenterol 2014; 20(13): 3582-3589 [PMID: 24707141 DOI: 10.3748/wjg.v20.i13.3582] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
80 Feld J, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, Khan AG, Lim SG, Locarnini SA, Ono SK, Sollano J, Spearman CW, Yeh CT, Yuen MF, LeMair A. World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. J Clin Gastroenterol. 2016;50:691-703. [PMID: 27623512 DOI: 10.1097/mcg.0000000000000647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
81 Vlachogiannakos J, Papatheodoridis GV. HBV: Do I treat my immunotolerant patients? Liver Int. 2016;36 Suppl 1:93-99. [PMID: 26725904 DOI: 10.1111/liv.12996] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
82 Tsang PS, Trinh H, Garcia RT, Phan JT, Ha NB, Nguyen H, Nguyen K, Keeffe EB, Nguyen MH. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol. 2008;6:569-574. [PMID: 18455697 DOI: 10.1016/j.cgh.2008.02.037] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
83 Marugán RB, Garzón SG. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol 2009; 15(4): 423-430 [PMID: 19152446 DOI: 10.3748/wjg.15.423] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
84 McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45-S55. [PMID: 19399792 DOI: 10.1002/hep.22898] [Cited by in Crossref: 464] [Cited by in F6Publishing: 438] [Article Influence: 35.7] [Reference Citation Analysis]
85 Di Bisceglie AM, King WC, Lisker-Melman M, Khalili M, Belle SH, Feld JJ, Ghany MG, Janssen HLA, Lau D, Lee WM, Ling SC, Cooper S, Rosenthal P, Schwarz KB, Sterling RK, Teckman JH, Terrault N; Hepatitis B Research Network (HBRN). Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. J Viral Hepat 2019;26:856-65. [PMID: 30974509 DOI: 10.1111/jvh.13104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
86 Lu Q, Lu C, Li J, Ling W, Qi X, He D, Liu J, Wen T, Wu H, Zhu H, Luo Y. Stiffness Value and Serum Biomarkers in Liver Fibrosis Staging: Study in Large Surgical Specimens in Patients with Chronic Hepatitis B. Radiology 2016;280:290-9. [PMID: 26885682 DOI: 10.1148/radiol.2016151229] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
87 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
88 Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 2008;6:1315-41. [DOI: 10.1016/j.cgh.2008.08.021] [Cited by in Crossref: 315] [Cited by in F6Publishing: 289] [Article Influence: 22.5] [Reference Citation Analysis]
89 Ohkoshi S, Hirono H, Watanabe K, Hasegawa K, Kamimura K, Yano M. Natural regression of fibrosis in chronic hepatitis B. World J Gastroenterol 2016; 22(24): 5459-5466 [PMID: 27350724 DOI: 10.3748/wjg.v22.i24.5459] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
90 Liu WC, Wu IC, Chiu YC, Tseng KC, Chen CY, Chiu HC, Cheng PN, Chang TT. Genotyping of immune-related loci associated with delayed HBeAg seroconversion in immune-active chronic hepatitis B patients. Antiviral Res 2020;176:104719. [PMID: 32004619 DOI: 10.1016/j.antiviral.2020.104719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Hsu YN, Pan CQ, Abbasi A, Xia V, Bansal R, Hu KQ. Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans. Dig Dis Sci 2014;59:865-71. [PMID: 24519522 DOI: 10.1007/s10620-014-3054-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
92 Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, Wei H. TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog. 2012;8:e1002594. [PMID: 22438812 DOI: 10.1371/journal.ppat.1002594] [Cited by in Crossref: 129] [Cited by in F6Publishing: 127] [Article Influence: 12.9] [Reference Citation Analysis]
93 Chen Z, Ma X, Zhao Y, Wang J, Zhang Y, Zhu Y, Wang L, Chen C, Wei S, Yang Z, Gong M, Shen H, Bai Z, Guo Y, Niu M, Xiao X. Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2015;2015:529636. [PMID: 26347789 DOI: 10.1155/2015/529636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
94 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
95 Liu W, He X, Huang F. Analysis of Serum MicroRNA-122 Expression at Different Stages of Chronic Hepatitis B Virus Infection. Biomed Res Int 2021;2021:9957440. [PMID: 34212044 DOI: 10.1155/2021/9957440] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Chi Z, Zhao W, Li JW, Liu H, Shao C, Zhao H, Gui-Qiang W. Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy. Clin Res Hepatol Gastroenterol 2020;:101563. [PMID: 33272888 DOI: 10.1016/j.clinre.2020.10.008] [Reference Citation Analysis]
97 Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360-1368.e1. [PMID: 22537444 DOI: 10.1053/j.gastro.2012.01.044] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 9.2] [Reference Citation Analysis]
98 McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010;14:381-396. [PMID: 20638020 DOI: 10.1016/j.cld.2010.05.007] [Cited by in Crossref: 113] [Cited by in F6Publishing: 95] [Article Influence: 9.4] [Reference Citation Analysis]
99 Yang J, Lu H, Guo R, Yan D, Ye P, Jin L, Chen C, Cao H, Diao H, Li L. Molecular profile of the T cell receptor beta variable in peripheral blood lymphocytes from chronic asymptomatic HBV carriers. Pathogens and Disease 2014;73:1-9. [DOI: 10.1093/femspd/ftu018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
100 Duddempudi AT, Bernstein DE. Hepatitis B and C. Clinics in Geriatric Medicine 2014;30:149-67. [DOI: 10.1016/j.cger.2013.10.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
101 Tseng T, Kao J. Treating Immune-tolerant Hepatitis B. J Viral Hepat 2015;22:77-84. [DOI: 10.1111/jvh.12370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
102 Liaw Y, Chu C. Hepatitis B virus infection. The Lancet 2009;373:582-92. [DOI: 10.1016/s0140-6736(09)60207-5] [Cited by in Crossref: 833] [Cited by in F6Publishing: 366] [Article Influence: 64.1] [Reference Citation Analysis]
103 Fiel MI. Pathology of chronic hepatitis B and chronic hepatitis C. Clin Liver Dis. 2010;14:555-575. [PMID: 21055682 DOI: 10.1016/j.cld.2010.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
104 Mamun-Al-Mahtab, Akbar SMF, Uddin H, Khan SI, Rahman S. Early termination of immune tolerance state of hepatitis B virus infection explains liver damage. World J Hepatol 2014; 6(8): 621-625 [PMID: 25232455 DOI: 10.4254/wjh.v6.i8.621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
105 Yang FQ, Yu YY, Wang GQ, Chen J, Li JH, Li YQ, Rao GR, Mo GY, Luo XR, Chen GM. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat. 2012;19:581-593. [PMID: 22762143 DOI: 10.1111/j.1365-2893.2012.01589.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
106 Yang J, He J, Lu H, Wei L, Li S, Wang B, Diao H, Li L. Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B. J Transl Med 2011;9:210. [PMID: 22152113 DOI: 10.1186/1479-5876-9-210] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
107 Andreani T, Serfaty L, Poupon R, Chazouilleres O. Need to Strictly Define Hepatitis B Virus Immunotolerant Patients to Avoid Unnecessary Liver Biopsy. Gastroenterology 2008;135:2155-6. [DOI: 10.1053/j.gastro.2008.08.060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
108 Lu J, Zhang S, Liu Y, Du X, Ren S, Zhang H, Ma L, Chen Y, Chen X, Shen C. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA. Liver Int 2015;35:1692-9. [DOI: 10.1111/liv.12753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
109 Kumar M, Sarin SK. Hepatitis B virus immunotolerant patients: need to differentiate patients with or without liver disease. Gastroenterology 2009;137:742-3. [PMID: 19563835 DOI: 10.1053/j.gastro.2009.05.058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
110 Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol. 2015;204:5-10. [PMID: 25540037 DOI: 10.1007/s00430-014-0369-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
111 Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol 2020;55:383-9. [PMID: 32016713 DOI: 10.1007/s00535-020-01665-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
112 Al-Qahtani AA, Al-Anazi MR, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khalaf NZ, Viswan NA, Al Ahdal MN. Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients. Liver Int. 2013; Oct 7. [Epub ahead of print]. [PMID: 24118788 DOI: 10.1111/liv.12347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
113 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 69.5] [Reference Citation Analysis]
114 Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008;48:335-52. [DOI: 10.1016/j.jhep.2007.11.011] [Cited by in Crossref: 791] [Cited by in F6Publishing: 748] [Article Influence: 56.5] [Reference Citation Analysis]
115 Li X, Zhou L, Gu L, Gu Y, Chen L, Lian Y, Huang Y. Veritable antiviral capacity of natural killer cells in chronic HBV infection: an argument for an earlier anti-virus treatment. J Transl Med 2017;15:220. [PMID: 29089040 DOI: 10.1186/s12967-017-1318-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
116 Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus AD, Pas SD, Janssen HL, Boonstra A. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology. 2015;62:87-100. [PMID: 25808668 DOI: 10.1002/hep.27805] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 11.3] [Reference Citation Analysis]
117 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
118 Adenlewo OJ, Adeosun PO, Fatusi OA. Medical and dental students' attitude and practice of prevention strategies against hepatitis B virus infection in a Nigerian university. Pan Afr Med J 2017;28:33. [PMID: 29138669 DOI: 10.11604/pamj.2017.28.33.11662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
119 Croagh CM, Lubel JS. Natural history of chronic hepatitis B: Phases in a complex relationship. World J Gastroenterol 2014; 20(30): 10395-10404 [PMID: 25132755 DOI: 10.3748/wjg.v20.i30.10395] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
120 Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009: Management of HBV: Consensus of JSH 2009. Hepatology Research 2011;41:1-21. [DOI: 10.1111/j.1872-034x.2010.00739.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
121 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
122 Choi HSJ, Tonthat A, Janssen HLA, Terrault NA. Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B. Hepatol Commun 2021. [PMID: 34894108 DOI: 10.1002/hep4.1875] [Reference Citation Analysis]
123 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
124 Ding Y, Wu FL, Sheng QJ, Zhao LR, Xia TT, Wang JY, Shi LL, Wang SL, Shan H, An P, Duan HY, Dou XG. Combination therapy with peginterferonα-2a and adefovir dipivoxil for HBeAg-positive chronic hepatitis B: A prospective multicenter cohort study. Shijie Huaren Xiaohua Zazhi 2012; 20(22): 2036-2042 [DOI: 10.11569/wcjd.v20.i22.2036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Chao DT, Lim JK, Ayoub WS, Nguyen LH, Nguyen MH. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther. 2014;39:349-358. [PMID: 24387289 DOI: 10.1111/apt.12590] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 6.5] [Reference Citation Analysis]
126 Mendy ME, McConkey SJ, Sande van der MA, Crozier S, Kaye S, Jeffries D, Hall AJ, Whittle HC. Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia. Virol J 2008;5:49. [PMID: 18416832 DOI: 10.1186/1743-422X-5-49] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
127 Wu I, Lai C, Han SB, Han K, Gordon SC, Chao Y, Tan C, Sievert W, Tanwandee T, Xu D, Neo B, Chang T. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010;51:1185-9. [DOI: 10.1002/hep.23424] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
128 Yang L, Ling W, He D, Lu C, Ma L, Tang L, Luo Y, Chen S. Shear wave-based sound touch elastography in liver fibrosis assessment for patients with autoimmune liver diseases. Quant Imaging Med Surg 2021;11:1532-42. [PMID: 33816189 DOI: 10.21037/qims-20-521] [Reference Citation Analysis]
129 Lin MH, Li HQ, Zhu L, Su HY, Peng LS, Wang CY, He CP, Liang XE, Wang Y. Liver Fibrosis in the Natural Course of Chronic Hepatitis B Viral Infection: A Systematic Review with Meta-Analysis. Dig Dis Sci 2021. [PMID: 34008117 DOI: 10.1007/s10620-021-07009-y] [Reference Citation Analysis]
130 Pan N, Jiang W, Sun H, Miao F, Qiu J, Jin H, Xu J, Shi Q, Xie W, Zhang J. KIR and HLA loci are associated with hepatocellular carcinoma development in patients with hepatitis B virus infection: a case-control study. PLoS One. 2011;6:e25682. [PMID: 21998681 DOI: 10.1371/journal.pone.0025682] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
131 Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lau G, Lee S, Gane EJ. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146:1240-1248. [PMID: 24462735 DOI: 10.1053/j.gastro.2014.01.044] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 12.6] [Reference Citation Analysis]
132 Al-Mahtab M, Akbar SM, Rahman S, Kamal M, Khan MS. Biochemical, virological, immunological and histopathological features of 702 incidentally detected chronic hepatitis B virus carriers in Bangladesh. Digestion 2012;86:1-5. [PMID: 22688441 DOI: 10.1159/000337529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
133 Xie HP, Yang HZ, Wu WK, Guan WB, Ke QS, Li YW, Dai M, Xiao GM, Zhang JS, Li YM. Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase. Chin J Integr Med 2014;20:94-100. [PMID: 24619234 DOI: 10.1007/s11655-013-1569-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
134 Tsai TY, Peng CY, Yang HI, Huang YL, Tao MH, Yuan SS, Lai HC, Hsieh SL. The human C-type lectin 18 is a potential biomarker in patients with chronic hepatitis B virus infection. J Biomed Sci 2018;25:59. [PMID: 30055605 DOI: 10.1186/s12929-018-0460-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
135 Gómez Rodríguez R, Guardiola Arévalo A, Gómez Moreno AZ, García Vela A, Gómez Hernando C, Rodríguez Merlo R, Sánchez Ruano JJ, de la Cruz Pérez G. [Characteristics of patients with chronic hepatitis B virus infection. analysis of a series of 474 patients]. Gastroenterol Hepatol 2013;36:243-53. [PMID: 23414836 DOI: 10.1016/j.gastrohep.2012.10.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
136 Bessone F. Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B. Liver Int. 2014;34:991-1000. [PMID: 25098191 DOI: 10.1111/liv.12499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
137 Wei L. Natural history of chronic hepatitis B virus infection: what determines prognosis after cirrhotic decompensation? J Gastroenterol Hepatol 2008;23:1631-2. [PMID: 19120855 DOI: 10.1111/j.1440-1746.2008.05576.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
138 Calvaruso V, Craxì A. Implication of normal liver enzymes in liver disease. Journal of Viral Hepatitis 2009;16:529-36. [DOI: 10.1111/j.1365-2893.2009.01150.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
139 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 661] [Article Influence: 45.4] [Reference Citation Analysis]
140 Rotman Y, Brown TA, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology. 2009;49:S22-S27. [PMID: 19399815 DOI: 10.1002/hep.22976] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
141 Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol. 2011;9:351-356.e3. [PMID: 21195790 DOI: 10.1016/j.cgh.2010.12.027] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
142 Gill US, Battisti A, Kennedy PTF. Emerging tools in the changing landscape of chronic hepatitis B management. Expert Rev Anti Infect Ther 2019;17:943-55. [PMID: 31738607 DOI: 10.1080/14787210.2019.1694906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
143 Kao J, Chen D. Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis. Curr hepatitis rep 2008;7:5-11. [DOI: 10.1007/s11901-008-0015-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
144 Liao Q, Wen J, Jiang K, Zhao Y, Ma X. Kushenin Combined with Adefovir Dipivoxil or Entecavir for Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2021;2021:8856319. [PMID: 33708259 DOI: 10.1155/2021/8856319] [Reference Citation Analysis]
145 Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008;23:1182-1192. [PMID: 18637060 DOI: 10.1111/j.1440-1746.2008.05400.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
146 Li Q, Lu C, Li W, Huang Y, Chen L. Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B. Oncotarget. 2017;8:45768-45776. [PMID: 28514753 DOI: 10.18632/oncotarget.17470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
147 Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol. 2011;55:183-191. [PMID: 21238520 DOI: 10.1016/j.jhep.2010.12.030] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 9.7] [Reference Citation Analysis]
148 Kawanaka M, Nishino K, Kawamoto H, Haruma K. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol 2021; 27(43): 7497-7508 [PMID: 34887645 DOI: 10.3748/wjg.v27.i43.7497] [Reference Citation Analysis]
149 Lee SA, Lee SY, Choi YM, Kim H, Kim BJ. Sex disparity in viral load, inflammation and liver damage in transgenic mice carrying full hepatitis B virus genome with the W4P mutation in the preS1 region. World J Gastroenterol 2018; 24(10): 1084-1092 [PMID: 29563753 DOI: 10.3748/wjg.v24.i10.1084] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578-10604. [PMID: 24927147 DOI: 10.3390/ijms150610578] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
151 Romani S, Hosseini SM, Mohebbi SR, Boonstra A, Sharifian A. Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection. J Viral Hepat 2017;24:776-88. [DOI: 10.1111/jvh.12699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
152 Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415-430. [PMID: 19669337 DOI: 10.1007/s12072-007-9033-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 4.5] [Reference Citation Analysis]